Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Gains from Sales and Divestitures (2022 - 2025)

Taysha Gene Therapies' Gains from Sales and Divestitures history spans 4 years, with the latest figure at $1.2 million for Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures rose 285.79% year-over-year to $1.2 million; the TTM value through Sep 2025 reached $1.2 million, up 285.79%, while the annual FY2024 figure was $323031.0, 831.7% up from the prior year.
  • Gains from Sales and Divestitures for Q3 2025 was $1.2 million at Taysha Gene Therapies, up from $1.0 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.2 million in Q3 2025 and bottomed at $17334.0 in Q1 2024.
  • The 4-year median for Gains from Sales and Divestitures is $192361.0 (2022), against an average of $335989.4.
  • The largest annual shift saw Gains from Sales and Divestitures plummeted 86.48% in 2023 before it soared 5953.64% in 2025.
  • A 4-year view of Gains from Sales and Divestitures shows it stood at $256481.0 in 2022, then tumbled by 86.48% to $34671.0 in 2023, then skyrocketed by 831.7% to $323031.0 in 2024, then skyrocketed by 285.79% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Gains from Sales and Divestitures are $1.2 million (Q3 2025), $1.0 million (Q2 2025), and $1.0 million (Q1 2025).